Outcomes and characteristics of non-melanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib
| dc.contributor.author | Laing, Heather | |
| dc.contributor.author | Garg, Mamta | |
| dc.date.accessioned | 2023-11-23T10:38:48Z | |
| dc.date.available | 2023-11-23T10:38:48Z | |
| dc.date.issued | 2023-11-14 | |
| dc.identifier.citation | Rampotas, A., Carter-Brzezinski, L., Somervaille, T. C., Forryan, J., Panitsas, F. P., Harrison, C. N., Witherall, R., Innes, A. J., Wallis, L., Butt, N. M., Psaila, B., Mead, A. J., Carter, M., Godfrey, A. L., Laing, H., Garg, M., Francis, S., Ewing, J., Teh, C. H., Cowan, H. B., … Lambert, J. (2023). Outcomes and Characteristics of Non-Melanoma Skin Cancers in Patients with Myeloproliferative Neoplasms on Ruxolitinib. Blood, blood.2023022345. Advance online publication. https://doi.org/10.1182/blood.2023022345 | en_US |
| dc.identifier.other | 10.1182/blood.2023022345 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12904/17898 | |
| dc.description.abstract | Non-melanoma skin cancers in ruxolitinib-treated MPN patients behave aggressively, with adverse features and high recurrence. In our cohort, mortality from metastatic NMSC exceeded that from myelofibrosis . Vigilant skin assessment, counselling on NMSC risks, and prospective ruxolitinib-NMSC studies are crucial. | |
| dc.description.uri | https://ashpublications.org/blood/article-abstract/doi/10.1182/blood.2023022345/498713/Outcomes-and-Characteristics-of-Non-Melanoma-Skin?redirectedFrom=fulltext | en_US |
| dc.language.iso | en | en_US |
| dc.subject | Non-melanoma skin cancers | en_US |
| dc.subject | ruxolitinib | en_US |
| dc.subject | MPN patients | en_US |
| dc.title | Outcomes and characteristics of non-melanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib | en_US |
| dc.type | Article | en_US |
| rioxxterms.funder | Default funder | en_US |
| rioxxterms.identifier.project | Default project | en_US |
| rioxxterms.version | NA | en_US |
| rioxxterms.versionofrecord | https://doi.org/10.1182/blood.2023022345 | en_US |
| rioxxterms.type | Journal Article/Review | en_US |
| refterms.panel | Unspecified | en_US |
| html.description.abstract | Non-melanoma skin cancers in ruxolitinib-treated MPN patients behave aggressively, with adverse features and high recurrence. In our cohort, mortality from metastatic NMSC exceeded that from myelofibrosis . Vigilant skin assessment, counselling on NMSC risks, and prospective ruxolitinib-NMSC studies are crucial. | en_US |
| rioxxterms.funder.project | 94a427429a5bcfef7dd04c33360d80cd | en_US |